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Abstract 
 
The viability of single and coaxial electrospray techniques to encapsulate model peptide - 
angiotensin II into near mono-dispersed spherical, nanocarriers comprising N-octyl-O-
sulphate chitosan and tristearin, respectively, was explored. The stability of peptide under 
controlled electric fields (during particle generation) was evaluated. Resulting nanocarriers 
were analysed using dynamic light scattering and electron microscopy. Cell toxicity assays 
were used to determine optimal peptide loading concentration (~1 mg/ml). A trout model was 
used to assess particle behaviour in vivo. A processing limit of 20 kV was determined. A 
range of electrosprayed nanoparticles were formed (between 100-300 nm) and these 
demonstrated encapsulation efficiencies of ~92 ±1.8 %. For the single needle process, 
particles were in matrix form and for the coaxial format particles demonstrated a clear core-
shell encapsulation of peptide. The outcomes of in vitro experiments demonstrated triphasic 
activity. This included an initial slow activity period, followed by a rapid and finally a 
conventional diffusive phase. This was in contrast to results from in vivo cardiovascular 
activity in the trout model. The results are indicative of the substantial potential for 
single/coaxial electrospray techniques. The results also clearly indicate the need to investigate 
both in vitro and in vivo models for emerging drug delivery systems. 
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1 Introduction 
 
Nanoparticles (NPs) can be synthesised in a wide range of sizes, shapes, and depending on 
the molecular basis of the structure, can be termed soft or hard. Nanotechnologies are used to 
achieve targeted delivery of drugs into cells or tissue in a specific manner, enhanced delivery 
of poorly water-soluble drugs, co-delivery of two or more drugs for combination therapy and 
visualization of drug delivery by combining therapeutic agents with imaging modalities [1]. 
 
The preparation of effective drug delivery systems still represents a timely ongoing challenge 
in medicine. However, there is a rapidly growing interest in NPs as drug delivery systems 
[2,3]. 
 
Both microparticles and NPs are used therapeutically to transport therapeutic agents 
through blood vessels and release the active at a desired target site [4].  Thus, the  design of 
ideal drug carriers to obtain sustained and controlled release have attracted much attention 
over the last few decades. These can also decrease the instability, variation of drug dosage 
and the concentration constant over the designated treatment period to maximise the efficacy 
of the therapeutic agent [5,6].  
 
Peptides have also gained interest as pharmaceutical actives but their delivery to target cells 
and stability (both during manufacturing and following administration) are obstacles in their 
deployment. To circumvent these problems, encapsulation of peptides and proteins has 
become the focus of an alternative approach for developing novel drug delivery systems. 
Generating nano-scale particles with the ability to control surface and morphological features 
has been shown to have a distinct impact on active protection and controlled release [1]. 
Several methods have been developed during the last two decades for preparation of NPs, 
where the active is dissolved, entrapped, encapsulated or attached to a NP. Commonly used 
methods for protein/drug encapsulation include solvent evaporation [7,8], nanoprecipitation 
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or solvent displacement [9,10], emulsification (which is a modified version of the solvent 
evaporation) [11], dialysis [12] and supercritical fluid technology [13]. However, these 
methods expose peptides to various factors affecting their stability such as organic solvents or 
high temperatures. These cause polymer degradation, which may promote drug deactivation 
[14]. Another critical concern related to engineering and mixing methods, includes the risk of 
drug inactivation due to structural breakdown or deformation arising from exposure to high 
temperatures or elevated shear stress during particle preparation. Shear stress at the 
aqueous/organic interface in emulsion methods is mainly responsible for protein denaturation 
and aggregation, and is generally difficult to avoid [15]. Moreover, low encapsulation 
efficiency and loading capacity, high initial burst release and broad size distribution of the 
particles are other negative attributes of emulsification processes [16,15]. These limits 
provide platforms for the development of new techniques with the ability to yeild more 
promising peptide-protien based drug delivery systems. 
 
Electrospraying (ES) is an ambient temperature platform technology that is currently being 
used for the preparation of a host of nanoscaled drug delivery morphologies [17,18,19].  
ES involves the application of an electric field to a liquid (formulation) flowing through a 
conducting capillary. The applied electrical charges compete with the inherent surface tension 
of the formulation (liquid) to deform this liquid droplet into a meniscus. Build-up of the 
electrical field at the capillary outlet eventually leads to a greater electrostatic force compared 
to relative surface tension. This causes elongation at the meniscus and susbequent 
disintegration of the initial liquid meniscus into fine droplets (micro- to nano-size). The 
charged droplets are collected in the direction of a grounded collector, whereas the solvent 
(vehicle) evaporates and solidifies resulting in particles [20].   
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The coaxial mode is a modified form of ES, where two or three capillary needles can be 
concentrically aligned to enable compartmentalisation within NPs. ES has also been used to 
generate bio-responsive polymer-peptides with key emphasis on particle size variations (100-
600 nm) [21]. ES allows sufficient control of characteristic shapes and sizes on the micro- to 
sub-micron scale integrating biopolymers and active molecules (e.g. proteins or growth 
factors) for controlled release [22]. Angiotensin II (Ang II) is an octapeptide hormone, which 
plays a vital role in cardiovascular homeostasis. Until recently, Ang II was only seen as a 
regulatory hormone controlling blood pressure and aldosterone release. It is now widely 
accepted that locally formed Ang II can activate the expression of many substances, including 
growth factors, cytokines, chemokines, and adhesion molecules, which are involved in 
diverse cellular processes, from cell growth/apoptosis, to fibrosis and inflammation [23].  
 
Tristearin is a solid lipid (triglyceride) that has been used in the development of drug delivery 
carriers [24,25]. Matrix systems prepared using triglycerides have shown to protect labile or 
altered agents from degradation and allowing controlled drug release [26]. Specifically, 
tristearin has been utilised to demonstrate efficient immobilisation of drugs through high 
pressure homogenisation which suggests the material is viable and applicable to more 
aggressive processing routes (e.g. when compared to emulsion methods). Tristearin based 
drug delivery systems are valuable in the development of drug carriers for improving their 
bioavailability by better diffusion through biological membranes [27,28]. Amphiphilic 
materials have also gained appreciable interest in recent times due to their adaptability within 
polar and non-polar environments. One such amphiphilic polymeric material is N-octyl-O-
sulphate chitosan (NOSC) which has demonstrated good potential biocompatibility, tissue 
distribution and good in vivo and in vitro outcomes (no acute toxicity) [29]. In this study, Ang 
II was used as a model peptide for encapsulation optimisation using the ES process. It also 
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has wide-ranging physiological roles throughout the body, acting via different subtypes of 
specific G protein-coupled receptors [30]. In this report, the preparation of core-shell peptide 
encapsulated nano structures via ES technique is described. The resulting structures were 
evaluated for cell toxicity, in vivo and in vitro peptide release. 
 
2 MATERIALS AND METHODS 
2.1 Materials 
 
N-octyl-O-sulphate chitosan (NOSC) and tristearin (MW891.48 g/mol) were used in this 
study. NOSC was synthesised as previously described [31]. Tristearin, solvents including 
dichloromethane (DCM), dimethyl sulfoxide (DMSO, > 99%), Heptane, human Ang II (MW 
1046.18 Da) were all purchased from Sigma-Aldrich, Dorset, UK. Water (HPLC grade) was 
puchased from Fisher Scientific, Loughborough, UK. Centrifugal filters (Amicon Ultra-4- 
ultra cell membrane 3 kDa MWCO) were purchased from Merck Millipore Ltd, Cork, 
Ireland. Float-A-Lyzer G2 dialysis filters (8-10 KD MWCO) were obtained from Spectrum 
Laboratories Inc, CA, US. MTT tetrazolium reduction assay [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] was purchased from Sigma-Aldrich, Dorset, UK. 
 
2.2 Solution preparation 
 
A series of solutions were prepared for the electrospraying process. For the first solution, 
NOSC was added to DMSO (0.1w/v %) and was mechanically stirred until complete 
dissolution. Ang II (10 mg) was added to 10ml of this solution and was mechanically stirred 
for a further 2 h ensuring complete dissolution. The second solution comprised NOSC, Ang II 
and Water (HPLC grade). For this, Ang II was dissolved in water (0.1 w/v %) through 
mechanical stirring. Once dissolved, NOSC (also 0.1 w/v %) was added to this solution and 
stirred for a further 2 h. For the final solution, tristearin was dissolved in DCM (1 w/v %) 
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through mechanical stirring at the ambient temperature (23 °C). The solutions are 
summarised in Table 1. 
 
2.3 Characterisation of solutions 
 
The solutions were characterised for surface tension, electrical conductivity and viscosity.  
Solution viscosity was determined using an Ostwald viscometer (size E) and applying  
equation (1) : 
𝜂 = 𝑘𝑡 
 
Where 𝜂 is the apparent viscosity, 𝑘 the viscosity constant for size E (0.362) and 𝑡 is the 
experimental time of transit of the liquid in the capillary. Surface tension was measured using 
a Kruss Easydyne V2-05 tensiometer (KRÜSS GmbH, Hamburg, Germany) using the plate 
method. Electrical conductivity was measured using a Hanna instrument HI-9033 (Hanna 
Instruments Inc., Woonsochet, US) conductivity probe. In all cases, the mean value of five 
consecutive readings was taken.  
 
2.4 Electrospraying process 
 
Ang II was encapsulated into NOSC and tristearin by the ES process based on a method used 
previously [17,18]. Tristearin is a triglyceride and is utilised in the food industry as an 
emulsifying agent. However, it is also used in other products as a hardening agent. For this 
study, tristearin was the ideal material to generate a core-shell which solidified rapidly after 
the ES process. It was therefore deployed in the outer needle during coaxial electrospraying 
to enable a rapid wax shell layer. The ES device (Profector Life Sciences Ltd, Ireland) 
consists of specifically designed stainless steel capillary nozzles (Rame-hart Instrument Co, 
NJ, US). The diameter of the single needle processing head was 508 μm. For the coaxial 
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needle setup, the inner and outer diameter were ~900 μm and 1900 μm respectively. In both 
instances, the capillary nozzle is connected to a high-voltage supply (capable of generating an 
electrical field of up to ~30 kV). Solutions were perfused into the nozzle using a 
programmable syringe pump (World Precision Instruments, Florida, US). Once optimised 
through applied voltage and flow rate (to enable the stable ‘cone-jet’ mode) [32] a more 
uniform particle production process was achieved [33]. For particle prepararion, the 
deposition distance was varied (at 25, 50 and 100 mm) determined as the distance between 
the tip of the needle to the collection substrate. For the single needle process, NOSC and Ang 
II solutions (1:1 ratio) were used. For the coaxial ES process the inner needle was supplied 
with Ang II and NOSC solutions (1:1 ratio) with the tristearin solution perfused through the 
outer needle. Details of applied voltage, working distance and other parameters are shown in 
Table 2. The samples for single needle ES were collected in a glass vial (15 ml of heptane) 
and for the coaxial ES process were collected in water (15 ml). The setup of the ES process 
utilised in this work is shown in Figure 1a, with a close-up of the processing needle shown in 
Fig. 1b. Encapsulation material formulations are shown in Fig. 1c. All experiments were 
carried out at the ambient temperature (23ºC). For individual experiments, initially optimised 
flow rates and applied voltages were determined when stable jetting was achieved (Fig. 1b).  
 
2.5 Particle size, distribution and zeta-potential measurment 
 
Dynamic light scattering (DLS) was used to measure the size distribution of NPs in the 
collection media (Malvern Zetasizer Nano-ZS, Malvern Instruments Ltd, UK). For imaging 
purposes, samples were collected on glass slides and dried for 24 h prior to studying by 
scanning electron microscopy (SEM/JEOL-6060LV, JEOL Ltd, Japan), operated at an 
accelarating volatge of 5 kV. Following drying, samples were gold coated for 2 min via a 
rotary-pumped sputter coater (Q150R ES, Quorum Technologies Ltd, East Sussex, UK) for 
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improving the conductivity of the sample surface. Transmission electron microscopy (TEM) 
was performed using TEM/JEOL-2000FX (JEOL Ltd, Japan) with an operating voltage of 80 
kV. TEM grids (Formvar films–200 Mesh Copper) were coated using the osmioum tetroxide 
and uranyl acetate solution (1 wt.% and 2 wt.% respectively) and air-dried before addition of 
samples and imaging. Zeta-potential was measured using a Nanobrook Omni analyser 
(Nanobrook Omni, Brookhaven, US) (ten replicates) and the mean value was obtained. For 
this NPs were collected and analysed in PBS (pH 7.4). 
 
2.6 Peptide stability through preliminary ELISA and HPLC analysis 
 
Human Ang II was used in all experiments. The stability of Ang II under ES conditions was 
assessed using High Performance Liquid Chromatography (HPLC/ Agilent Technologies, 
US) and enzyme-linked immunosorbent assay (ELISA/ Enzo Life Sciences Ltd, UK). 
Samples were prepared using flow rates of; 5, 10 and 20 µl/min and each flow rate was 
subjected to applied voltages of 20 and 30 kV. For HPLC a Phenomenex Aeris™ Peptide 
column (Phenomenex Ltd, UK) was used (250×4.6 mm, 3.6 μm/100 Å, using an 
acetonitrile/water (50:50 ratio) solvent system with 0.1 v/v% trifluoroacetic acid). A 
calibration curve was constructed with Ang II concentrations of 50,100,200,400,600 and 800 
µg/ml. Peptide analysis was performed at 214 nm.  In addition, the stability of Ang II was 
also studied through direct quantitation by ELISA as per manufacturer’s instructions. A 
standard series of Ang II (3.91-10,000 pg/ml) was prepared. The assay kit employed 
immobilised anti-Ang II antibodies to capture the samples or standard Ang II, which compete 
for binding with later added biotinylated Ang II, the presence of which is then detected 
through amplification by streptavidin conjugated to horseradish peroxidase (HRP), followed 
by colorimetric measurement of the HRP-catalysed reaction at 450 nm. Thus, in this assay, 
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the amount of signal detected was inversely proportional to the level of Ang II in the sample. 
Graph Pad Prism 6.01 software was used for data evaluation.  
 
2.7 Drug loading and release study 
 
The quantiity of drug loaded in NPs was determined using centrifugal filters (Amicon Ultra-
4- ultracell membrane 3 kDa MWCO) which were used to separate loaded particles from free 
Ang II, quantified using HPLC analysis. A known quantity (15 mg) of electrosprayed NPs 
were added to the centrifugal filters and centrifuged for 30 min at 4000 rpm to separate the 
NPs from the untrapped peptide in flow-through filtered solutions. Filtered solutions were 
then analysed by HPLC (using an acetonitrile/water (50:50 ratio) solvent system with 0.1 
v/v% trifluoroacetic acid) as described above. Ang II release from electrosprayed NPs was 
performed using Float-A-Lyzer G2 dialysis filters. The filters were prepared according to the 
manufacturer’s instructions. Electrosprayed NPs were added to the filters and incubated in 15 
ml of PBS at 37ºC (under agitation). At specified time intervals aliquots of the release 
medium were taken (1 ml) and an equal volume of fresh PBS was added. Ang II was 
quantified by HPLC as described above. All studies were performed in triplicate and mean 
values are reported. A control experiment to determine the release behaviour of the free Ang 
II was also performed. The release study was carried out over a 48 h period. Encapsulation 
effeciency was confirmed using equation (2): 
 
Encapsulation efficiency (EE) =
Actual amount of drug loaded in NPs
Theoretical amount of drug loaded in NPs
× 100% 
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2.8 In vitro cell culture 
 
To evaluate the potential biocompatibility of the electrosprayed NPs, the mouse brain b-End 
3 endothelial cell line was used [34]. b-End 3 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM), supplemented with 10% foetal calf serum (FCS), 1% non-
essential amino acids, L-ascorbic acid (0.150 g/l), 2 mM L-glutamine, 0.02 M HEPES, 
penicillin (100 U/ml) and streptomycin (0.1 mg/ml) (all purchased from Sigma, Dorset, UK). 
B-End 3 cells were maintained at 37ºC in a humidified incubator with 5% CO2.  
 
2.9 MTT toxicity assay  
 
Cells were seeded at 1 × 10
5 
cells per well (using a 96 well plate, Nunc, Fisher Scientific, 
Loughborough, UK) and were incubated for 24 h in culture media. 100 µL of the 
electrosprayed NPs, unloaded and loaded with Ang II, were added to selected wells. The cells 
were further incubated for 24 h. 50 µL of MTT reagent (prepared in a physiological solution) 
was then added to cells and incubated for 2 h as per manufacturer’s instructions. The negative 
control contained media only. After 2 h of MTT incubation, the culture media was removed 
and cells were washed with 100 µL of Dulbecco’s phosphate buffered saline (PBS) prior to 
the addition of 100 µL of dimethylsulfoxide (DMSO) to each well to dissolve formazan 
precipitates. The quantity of formazan, which is proportional to the number of viable cells 
was measured via change in absorbance at 570 nm using a spectrophotometer (POLARstar 
OPTIMA, BMG Labtech, Bucks, UK). Also, phase-contrast microscopy images of cells were 
captured using a Leica inverted DMIRB microscope (attached to a Leica DMC 2900 camera, 
Milton Keynes, UK). 
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2.10 In vivo study using trout model 
 
In vivo experiments were performed on unanaesthetised adult rainbow trout (Oncorhynchus 
mykiss) weighing approximately 250 g (Fig. 1d). The technique used for placement of the 
electrocardiographic electrodes, recording of the ventilation, cannulation of the dorsal aorta, 
intra-arterial (IA) injection of the peptide, and data acquisition and analysis of the 
cardiovascular variables have been described previously in detail [35,36]. The ventilation 
signal was only used here to monitor the recovery of normal baseline ventilation after surgery 
and no quantification of the ventilatory variables was performed. The dorsal aortic blood 
pressure (PDA) and the heart rate (HR) were monitored and quantified continuously. Briefly, 
after two post-operative days, recording sessions of 30 min were started. 5 min after the 
beginning of the recordings, the trout firstly received an IA injection of vehicle (Ringer’s 
trout solution, n=13) followed 30 min later with an IA injection of Ang II (50 pmol/trout; ~ 
200 pmol/kg, n=8), or tristearin NPs loaded with Ang II (equivalent to 50 pmol/trout, n=6). 
The dorsal aortic blood pressure (PDA) and the heart rate were monitored continuously (n=8-
13). 
 
 2.11 Statistical analysis 
 
The data from MTT assay was analysed statistically using one-way ANOVA with Bonferroni 
post hoc test; P < 0.05 was considered as statistically significant. The in vivo data were 
expressed as means ± S.E.M for each 5 min period, for which two-way ANOVA for repeated 
measures followed by the Bonferroni test for comparisons between groups at selected time-
points. The criterion for statistical difference between groups was P < 0.05. Two-way 
ANOVA was also employed for ELISA and HPLC analysis. The statistical tests were 
performed using Prism 6.01 (GraphPad, San Diego, CA). 
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3 Results and Discussion 
 
The ES process (Fig. 1) was successful in generating spherical core-shelled NPs with a 
narrow size distribution. At specific ES parameters, through electrified capillary needles 
(single and coaxial), the liquids adopted a conical shape (Fig. 1b). The ES process is highly 
dependent on solution (process material) properties in obtaining a stable cone-jet for 
controlled generation. This process requires the existence of an induced electric field at the 
tip of the needle plus a minimum electrical conductivity of the solution to be electrosprayed. 
However, the surface tension is a competing force and it must be overcome by the solution’s 
electrical conductivity, thus permitting the atomisation process. Furthermore, the viscosity of 
the solution is known to influence the morphology and size of the resulting structures; for 
concentric double-layered particles, the viscosity of the outer-needle liquid should be 
optimised in order to accommodate cone formation and break-up (e.g. Reynold number) 
efficiently through electrical stress flow homogeneity throughout the solution and to the inner 
phase [37,38]. All solutions employed in the present study were characterised (Table 1). All 
values for surface tension were below that of water, making them suitable for ES [39]. 
However, in coaxial mode conventional single needle limits are overcome. For example 
Loscertales et al. (2002) sprayed oil (not viable for ES alone) with a conducting liquid [40]. 
All solutions displayed low viscosity, which alludes to the potential of particle generation. 
Finally all materials demonstrated electrical conductivity and those exhibiting the lowest 
values (e.g. DCM, ~1.0×10
−5
 Sm
-1
) have been utilised in previous studies [41]. This also 
suggests current formulations prepared from tristearin and Ang II are able to provide the 
electrical stress required for jet formation. 
 
The encapsulation of proteins (e.g. insulin, BSA and lysozyme) and peptides in polymeric 
microparticles and NPs has been studied previously. However, there are limited studies 
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focusing on the effect of the applied electrical field on the stability of the peptide under 
investigation [42,43,41]. In addition, reported electrical field values for peptide/protein 
encapsulation have generally been below 20 kV [41,44]. In this study, the stability of Ang II 
was investigated using conventional HPLC (Fig. 2a) and ELISA (Fig. 2b). The stability of 
Ang II under ES conditions with different controlled parameters (flow rates at 5, 10 and 20 
µl/min; applied voltage at 20 and 30 kV) were studied. For higher flow rates it was found that 
there was no observable change to the peptide even at high voltages (Fig. 2) by means of 
detection using HPLC. However, with ELISA (Ang II amount recognised by antibody) there 
is a difference between samples collected at different applied electric fields (P < 0.0001). In 
this instance the flow rate had no significant impact. Based on these findings, and by 
providing a stable cone-jet for the collection of NPs, an applied electric field below 20 kV 
was selected. As the ES process is largely driven by flow rate and applied electric field, 
exploratory conditions were used to optimise the process. 
 
An ES single needle process was employed (flow rate of 3 µl/min and applied voltage of 15-
19 kV) to generate NPs containing Ang II embedded in NOSC matrix. Ang II loaded NPs 
were collected in heptane (working distance 100 mm). Following analysis (using DLS) they 
were found to have an average size of 105.7 nm ± 4 nm (Fig. 3a). However, when the same 
initial matrix material NOSC with Ang II was used (inner needle) during the coaxial ES 
process (tristearin in the outer layer), two peaks resulted, giving rise to a bimodal distribution. 
The first peak demonstrated a mean particle diameter of ~250 nm. The second peak occurred 
on the micron scale (~5 µm) which was a clearly different to the former (Fig. 3b). This 
correlated with the particle generating ES process, which exhibited intermittent jetting 
instabilities during the preparation of  NOSC-Ang II and tristearin particles (coaxial ES). The 
polydispersity of the particles also increased appreciably (~73%). The encapsulation (coaxial 
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ES) of Ang II (in water) alone into a tristearin core-shell resulted in a more uniform particle 
size and distribution (178.28 nm). By decreasing the working distance from 50mm to 25mm 
resulted in an increase in the average particle size from 178.28 nm (±20 nm) to 267.48 nm 
(±30 nm) (Fig. 3c and Fig. 3d). The parameters and outcomes have been summarised in Table 
2.  
To assess the morphology of NPs, SEM and TEM were used. Micrographs (Fig. 4a) show 
spherical particles for electrosprayed samples (Table 2) and the size of particles correlated 
with values obtained using DLS. Fig. 4b shows particles generated using the coaxial ES 
process (tristearin in outer layer, NOSC and Ang II in inner layer) where a broad size of 
particles can be observed. However, coarse 5µm particles detected on DLS are not evident, 
but in this instance smaller (1µm-500 nm) particles can be observed. This may also suggest 
some degree of agglomeration during DLS analysis. However, even within these samples 
there exists a coarser distribution which can also be attributed to the unstable jetting observed 
using NOSC in the coaxial ES process. Removal of NOSC from the formulation (using 
tristearin in the outer layer and Ang II in inner layer) gave rise to a more uniform particle size 
distribution, which also exhibited spherical morphologies (Fig. 4c). TEM was used to assess 
the degree of core-shell encapsulation. Both samples c and d (Table 2/ Fig. 4d and 4e) 
demonstrated well defined core-shelled stuctures with hollow centres. The layering of 
tristearin and encapsulated Ang II was visible. The effect of deposition distance, was 
confirmed using particle size analysis and a clear difference in size distribution and 
uniformity was observed (Fig. 4f). In some artefacts during the consolidation process (droplet 
to particle formation), the inner Ang II formed bridges (Fig. 4g), which remained intact once 
solidified. This again confirmed the hollow nature of the particles. The well defined 
representative structure of NPs is shown in Fig. 4h. HPLC analysis of the peptide content in 
NPs samples were calculated to be ~92% ±1.8. These vlaues, however, showed a disparity 
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between those obtained when using ELISA (Fig. 2), where a significant reduction in Ang II 
stability/retention was detected at high voltage (P <0.0001) indicating chemical change or 
alteration of the peptide during the ES process at high electric fields (20 kV or greater). The 
zeta potential of NPs (in PBS, pH 7.4) was -4.58 ± 2.52 mV (range between -7.06 to -2.03 
mV), which suggests these structures will have a tendency to agglomerate. The parametric 
optimisation through mode-map selection (preliminary optimisation) was below 20 kV, and 
in all instances HPLC was used further to assess release of encapsulated Ang II from core-
shelled tristearin NPs. 
 
In vitro validation using free Ang II (as a control) demonstrated a release of at least 90% of 
peptide across dialysis membranes under 4 h and total release at 6 h (99% of the control 
concentration). In contrast, the nano-encapsulation of Ang II within tristearin core-shells 
from nanocapsules demonstrated a triphasic release profile, which has been observed in other 
encapsulation methods [45]. Upto 5 h the cumulative release quantity of Ang II was ~5%, 
and during this time the release was sustained, this being the first phase. From 5 h onwards, 
the second phase demonstrated a rapid release of an additional ~15% of Ang II, which could 
be due to free Ang II (non-embedded or adsorbed onto the inner core-shell tristearin matrix) 
diffusing out of nanocapsules due to fractures or pores arising from the hydrolysis of ester 
groups within its structure [46,47]. The final phase demonstrated a typical matrix-based 
release profile where adsorbed Ang II in the inner core was released and then subsequent 
embedded Ang II (into the matrix) was also released. This process however was gradual, with 
50% Ang II release at 15 h and 75% release at 24 h. A further ~15% Ang II was released by 
48 h (Fig. 5) . Based on in vitro release findings, the encapsulation of Ang II using coaxial ES 
is a highly successful method to control release, or moreover, a method to encapsulate the 
drug and permit release once localised in the desired tissue. This is a common problem with 
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non-core shelled (non-layered matrix) technologies providing inadequate layered 
encapsulation. While tristearin is prone to degradation factors (e.g. water and light when 
using PBS in an open system), an in vivo model would also introduce further host 
environmental factors such enzymatic, chemical and mechanical actions [48,49]. An in vivo 
trout model was used (Fig. 1d) to assess the activity of the NPs. Results demonstrated that IA 
injection of vehicle (trout’s ringer solution) induced no change in the trout’s cardiovascular 
variables, as expected (Fig. 6 a and b). In contrast, the IA injection of free Ang II provoked 
an increase in the blood pressure (Fig. 6a), indicating successful delivery of nano-
encapsulated Ang II. A two-fold increase in baseline value peaked 3 min after the injection. 
This increase in blood pressure was transient since baseline PDA was reached by the end of 
the recording. IA injection of tristearin-encapsulated Ang II was as potent as free Ang II for 
inducing a sharp increase in PDA. Interestingly, no delayed response could be observed in the 
effect of tristearin-encapsulated Ang II in this study, as the speed of response of encapsulated 
Ang II appeared to mirror that of the free peptide. However, tristearin-encapsulated Ang II 
had a more sustained physiological effect since its hypertensive effect persisted until the end 
of the recording (P<0.05). After IA injection of vehicle, free Ang II and tristearin-
encapsulated Ang II, the change in HR was not statistically significant between groups (Fig. 
6b). This could be explained due to two reasons. The first relates to the adminstration method 
of the NP formulation. The shearing effect encountered during infusion may have lead to 
fracture of the NP core-shell; which presents an opportunity for immediate release of Ang II. 
Secondly, potential enzymatic, physiological and anatomical features in the trout model 
which could not be accounted for in the PBS drug-release study may have led to damaged NP 
core-shell systems (either mechanical or chemical). This again would have led to rapid 
release. Only changes in blood pressure (PDA) were significant (i.e. based on differences in 
PDA after administration of free Ang II, vehicle and tristearin-Ang II NPs) at time-points 10, 
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15, 20 and 25 minutes (* P<0.05). In addition, at the 30 minute time-point, PDA was 
significantly elevated for the tristearin-Ang II NPs when compared to the vehicle and free 
Ang II (+ P<0.05). There is no change in HR at any time. 
 
For the rapid and accurate determination of cell viability, a method that was originally 
developed as an assay for survival of mammalian lymphoma cells is based on the 
transformation and colorimetric quantification of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] [50]. Mitochondria reduce tetrazolium salts and thereby form 
non-water-soluble violet formazan crystals within the cell. The amount of these crystals can 
be determined spectrophotometrically and serves as an estimate for the number of 
mitochondria and hence the number of living cells in the sample [51]. These features 
are taken advantage of in cytotoxicity or cell proliferation assays and are widely to study cell 
viability in toxicology and cell biology. The results of the MTT assay for loaded and 
unloaded NPs demonstrated significant cellular toxicity only at the highest concentration of 
electrosprayed NPs (1 mg/ml) compared to the control (cells and media). No significant 
differences in toxicity were observed between loaded vs. unloaded NPs. This effect could 
relate to a real physiological effect through some unknown NP interaction mechanism, or 
may relate to residual levels of DCM in NP base solvents which could accumulate at higher 
concentrations of NPs. Phase contrast imaging of cell culture tests with NPs after 24 h 
incubation are shown in Fig. 7a-c, respectively. In some areas, localised agglomerations of 
NPs could be observed (Fig. 7c), but in general NPs either loaded or unloaded were well 
tolerated causing no obvious morphological changes in cells. NP concentrations lower than < 
0.5 mg/ml only resulted in very limited levels of toxicity as measured by MTT assay (Fig. 
7d). However, no significant differences in toxicity were obsevered between loaded and 
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unloaded NPs, and this confirms cellular tolerance to NPs loaded with Ang II (Bonferroni* = 
P<0.05, (Fig. 7d)). 
 
4 Conclusions 
 
In this work, successful encapsulation of Ang II into tristearin core-shell nanoparticles 
(average size of 267.48 nm and 178.28 nm) via a coaxial ES technique is demonstrated. The 
single needle process proved to be viable in the preparation of matrix (non-core shelled) 
particles (~105 nm) using advanced polymeric materials e.g. NOSC. However, when used in 
a coaxial ES system a bimodal particle distribution resulted with a large size difference. The 
stability of Ang II, when subjected to high-voltage electric fields, was evaluated using ELISA 
and HPLC, indicated a potential use of ELISA as a preliminary analytical tool for peptide 
stability during ES encapsulation. These results indicated that the structure of Ang II was not 
affected below 20 kV and low flow rates (5 µL) was applied (P< 0.0001). The in vitro release 
of Ang II from tristearin NPs appeared to show a triphasic release pattern which was 
sustained. This was in sharp contrast to NP behaviour using in vivo models. Upon delivery of 
free Ang II and loaded NPs, very similar physiological activity was observed, although NPs 
demonstrated prolonged activity towards the end of the study. This also suggests some 
anatomical or environmental (chemical) features of the trout model that need to be taken into 
account. MTT toxicity assay effectively determined an acceptable loading concentration for 
loaded or unloaded encapsulated NPs, generating no acute  toxicity or morphological effects 
in vitro. Furthermore, in vivo experiments (using trout model) indicated a sustained 
hypertensive action when Ang II was administered in tristearin-encapsulated form and 
consequently confirmed the bioavailability of the peptide. The outcomes of both in vitro and 
in vivo release studies indicate the substantial potential of single/coaxial ES techniques for 
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the fabrication of NPs or multi-layered nanocapsules that can be used in the development of a 
variety of applications for the delivery of water-soluble peptides. 
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Figure Captions  
 
Figure 1 Experimental setup showing (a) the electrospraying device and the peripheral 
components (b) close-up of the processing needle (stable cone-jet mode) (c) with 
encapsulated material formulations (d) setup for in vivo trout model. 
 
Figure 2 Stability studies of Ang II subject to high-voltage electric field at different flow 
rates: results obtained by (a) HPLC and (b) ELISA. 
 
Figure 3 Size distribution report (intensity) of encapsulated NPs generated by DLS; (a) 
sample a (single needle) containing the model peptide Ang II embedded in NOSC matrix 
with average size of 105.7 nm ± 4 nm (b) sample b (coaxial ES) containing NOSC and Ang II 
(inner layer) and tristearin (outer layer) with coarse particles (micron scale ~5 µm) (c) sample 
c (coaxial ES) containing Ang II (inner layer) and tristearin (outer layer) with average size of 
178.28 nm and working distance of 50 mm (d) sample d with the same formulation of sample 
c and working distance of 25 mm, average size of 267.48 nm.  
 
Figure 4 Scanning and Transmission electron microscopy (SEM, TEM) images showing Ang 
II loaded NOSC and tristearin NPs; (a) electron micrograph of NOSC and Ang II using single 
needle at operating voltage of 15-19 kV and flow rate of 3 µl/min (b) electron micrograph of 
NOSC and Ang II (inner layer) and tristearin (outer layer) using coaxial ES needles at 
operating voltage of 15-17.9 kV and flow rate of 5 and 11 µl/min for inner and outer layer 
respectively (c) electron micrograph of Ang II (inner layer) and tristearin (outer layer) using 
coaxial ES needles at operating voltage of 15-17.9 kV and flow rate of 5 and 11 µl/min for 
inner and outer layer respectively and (d-f) TEM images showing the generated encapsulated 
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NPs with core-shell structures and hollow centres (g) encapsulated Ang II bridging across the 
NP core (h) illustrated structure of encapsulated NPs.  
 
Figure 5 In vitro release profile of tristearin NPs loaded Ang II (vs. free peptide used as 
control). 
 
Figure 6 Time-course curves for (a) the in vivo dorsal aortic blood pressure (PDA; in 
kilopascal/kPa) and (b) heart rate (HR, beats per minute/bpm) effects of vehicle (Ringer 
solution, in black, n=13), free Ang II (50 pmol/ per trout; ~200 pmol/kg, in red, n=8), and 
tristearin-encapsulated Ang II (equivalent to 50 pmol/ per trout, in blue, n=6) in the 
unanaesthetised trout. The arrow indicates the time of intra-arterial injection. The curves 
represent mean (± S.E.M at selected times). * P< 0.05 free Ang II and tristearin-encapsulated 
Ang II vs vehicle at corresponding time points. + P < 0.05 tristearin-encapsulated Ang II vs 
vehicle and free Ang II. No statistically significant change occurred for HR between groups. 
 
Figure 7 MTT toxicity assay of unloaded and Ang II loaded NPs and phase contrast 
microscopy images of the cells after 24 h incubation (a) phase contrast micrograph of media 
only (control) (b) phase contrast micrograph of mouse brain endothelial cells after 24 h 
incubation without NPs and (c) with added NPs (d) MTT toxicity assay data using media 
only, unloaded and loaded NPs with Ang II after 24 h incubation the cells (data were 
analysed using one way ANOVA with Bonferroni test * = P< 0.05 relative to control).  
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Figure 1  
 
 
 (d) 
[NPs = Nanoparticles, Ang II = Angiotensin II, ECG= Electrocardiography] 
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Tables 
 
 
Table 1 Physical properties of the solutions and solvents used in this study 
 
 
 
 
 
Table 2 Size distribution data for single and layered (NOSC, Ang II and tristearin) structures 
 
 
 
 
 
 
 
 
Solvent or Solution 
Surface 
Tension 
(mN m
-1
) 
Viscosity 
(mPa s) 
Electrical 
Conductivity 
10
-2
 (Sm
-1
) 
NOSC (0.1w/v %) in DMSO 42.1 ±2.2 2.65 ±0.07 1.050 ±0.0200 
Angiotensin II (0.1w/v %) in water (HPLC grade) 56.0 ±1.8 1.39 ±0.05 1.160 ±0.0100 
Tristearin (1w/v %) in DCM 25.8 ±1.2 2.51 ±0.04 0.002 ±0.0001 
Water (HPLC grade) 71.8 ±0.5 1.40 ±0.02 0.070 ±0.0020 
DCM 28.4 ±2.1 1.84 ±0.03 0.001 ±0.0003 
  DMSO 44.0 ±1.5 2.31 ±0.04 0.012 ±0.0004 
Samples 
Applied 
Voltage 
(kV) 
Inner flow 
rate 
(µl/min) 
Outer flow 
rate 
(µl/min) 
Working 
distance 
(mm) 
Average Size 
(nm) 
SD 
(±nm) 
Polydispersity 
(%) 
a (Single ES) 15-19 3 × 100 105.7 3.64 18 
b (Coaxial ES) 15-17.9 5 11 50 255.56 & 5490  48.09 & 
155.4 73 
c (Coaxial ES) 15-17.9 5 11 50 178.28 11.9 24 
d (Coaxial ES) 15-17.9 5 11 25 267.48 31.68 29 
[DCM = dichloromethane, DMSO = Dimethylsulfoxide, NOSC= N-octyl-O-sulphate chitosan] 
[Ang II = Angiotensin II, NOSC= N-octyl-O-sulphate chitosan, ES = Electrospray] 
